TITLE

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

PUB. DATE
January 2008
SOURCE
BMC Genetics;2008, Vol. 9, p352
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
43750491

 

Related Articles

  • Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture. Ackermann, Maximilian; Morse, Brent; Delventhal, Vera; Carvajal, Irvith; Konerding, Moritz // Angiogenesis;Dec2012, Vol. 15 Issue 4, p685 

    Increasing experimental evidence suggests that IGF-1 may modulate tumor angiogenesis via activation of the expression of VEGF in Ewing sarcomas and rhabdomyosarcomas. This study investigates the effects of the PEGylated Adnectinsâ„¢ CT-322, a VEGFR2-inhibitor and AT580Peg40, an IGF-1R...

  • Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases Lee, Lucy; Sharma, Sunil; Morgan, Bruno; Allegrini, Peter; Schnell, Christian; Brueggen, Josef; Cozens, Robert; Horsfield, Mark; Guenther, Clemens; Steward, Will P.; Drevs, Joachim; Lebwohl, David; Wood, Jeanette; McSheehy, Paul M. L. // Cancer Chemotherapy & Pharmacology;Jun2006, Vol. 57 Issue 6, p761 

    PTK/ZK is a novel, oral angiogenesis inhibitor that specifically targets all 3 vascular endothelial growth factor (VEGF) receptor tyrosine kinases and is currently in phase III clinical trials. In early clinical trials, PTK/ZK demonstrated a dose-dependent reduction in tumor vascular parameters...

  • Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Thaker, Premal H.; Han, Liz Y.; Kamat, Aparna A.; Arevalo, Jesusa M.; Takahashi, Rie; Chunhua Lu; Jennings, Nicholas B.; Armaiz-Pena, Guillermo; Bankson, James A.; Ravoori, Murali; Merritt, William M.; Lin, Yvonne G.; Mangala, Lingegowda S.; Tae Jin Kim; Coleman, Robert L.; Landen, Charles N.; Yang Li; Felix, Edward; Sanguino, Angela M.; Newman, Robert A. // Nature Medicine;Aug2006, Vol. 12 Issue 8, p939 

    Stress can alter immunological, neurochemical and endocrinological functions, but its role in cancer progression is not well understood. Here, we show that chronic behavioral stress results in higher levels of tissue catecholamines, greater tumor burden and more invasive growth of ovarian...

  • SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model. Ackerman, Rachel; Backer, Joseph M.; Backer, Marina; Skariah, Sini; Hamby, Carl V. // Toxins;Sep2010, Vol. 2 Issue 9, p2242 

    SLT-VEGF is a recombinant cytotoxin comprised of Shiga-like toxin (SLT) subunit A fused to human vascular endothelial growth factor (VEGF). It is highly cytotoxic to tumor endothelial cells overexpressing VEGF receptor-2 (VEGFR-2/KDR/Flk1) and inhibits the growth of primary tumors in...

  • The Potency of Refined Mouse Models: Implications for Clinical Trials. Graeser, Ralph; Fiedler, Ulrike; Esser, Norbert; Klotzbuecher, Andrea; Weber, Holger; Schaechtele, Christoph // Current Cancer Therapy Reviews;2010, Vol. 6 Issue 1, p62 

    Many promising anti-cancer compounds fail in the clinical phase despite extensive testing in animal models. Reasons for this failure are varied, ranging from inadequate mouse models to dosing schemes that cannot be applied in humans. The apparent shortcomings of exisiting pre-clinical...

  • Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models. Duignan, Inga J.; Corcoran, Erik; Pennello, Anthony; Plym, Mary Jane; Amatulli, Michael; Claros, Nidia; Iacolina, Michelle; Youssoufian, Hagop; Witte, Larry; Samakoglu, Selda; Schwartz, Jonathan; Surguladze, David; Tonra, James R. // Neoplasia;Jan2011, Vol. 13 Issue 1, p49 

    The benefits of inhibiting vascular endothelial growth factor (VEGF) signaling in cancer patients are predominantly attributed to effects on tumor endothelial cells. Targeting non-endothelial stromal cells to further impact tumor cell growth and survival is being pursued through the inhibition...

  • Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Wood, Laurence; Pan, Zhen-Kun; Guirnalda, Patrick; Tsai, Peter; Seavey, Matthew; Paterson, Yvonne // Cancer Immunology, Immunotherapy;Jul2011, Vol. 60 Issue 7, p931 

    The FDA approval of bevacizumab (Avastin, Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for...

  • Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model. Angst, Eliane; Chen, Monica; Mojadidi, Michelle; Hines, O.; Reber, Howard; Eibl, Guido; Hines, O Joe; Reber, Howard A // Molecular Imaging & Biology;Nov2010, Vol. 12 Issue 6, p570 

    Purpose: Angiogenesis is essential for physiological processes as well as for carcinogenesis. New approaches to cancer therapy include targeting angiogenesis. One target is VEGF-A and its receptor VEGFR2. In this study, we sought to investigate pancreatic cancer angiogenesis in a...

  • Tolfenamic Acid and Pancreatic Cancer Growth, Angiogenesis, and Sp Protein Degradation. Abdelahim, Maen; Baker, Cheryl H.; Abbruzzese, James L.; Safe, Stephen // JNCI: Journal of the National Cancer Institute;6/21/2006, Vol. 98 Issue 12, p855 

    Background: Sp1, Sp3, and Sp4 are transcription factors that regulate cell proliferation and vascular endothelial growth factor (VEGF) expression and are overexpressed in many cancer cell lines. For some cancers, Sp1 overexpression is associated with poor survival. Cyclooxygenase inhibitors...

  • Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer.  // PLoS ONE;2009, Vol. 4 Issue 11, p1 

    The article offers information on a study related to immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. It is stated that the effect of blocking VEGF activity in solid tumors extends beyond inhibition of angiogenesis. However, no studies have compared...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics